Home / Healthcare/ Sanofi trumps Novo Nordisk with agreed $ 4.8 B bid for Ablynx

Sanofi trumps Novo Nordisk with agreed $ 4.8 B bid for Ablynx


Comments / {{hitsCtrl.values.hits}} Views / Tuesday, 30 January 2018 00:00


PARIS (Reuters): Sanofi has agreed to buy biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking the French drug maker’s second major takeover this month after buying Bioverativ.

The companies said Sanofi would pay 45 euros per share in cash for Ablynx, a premium of 21.2% over the Belgian firm’s closing stock price on Friday. The deal comes after Ablynx had earlier rejected a lower offer from Denmark’s Novo Nordisk.

“With Ablynx, we continue to advance the strategic transformation of our research and development, expanding our late-stage pipeline and strengthening our platform for growth in rare blood disorders,” Sanofi Chief Executive Officer Olivier Brandicourt in the companies’ joint statement.

Earlier this month, Sanofi had agreed to buy US haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases.

Sanofi said Ablynx would boost long-term value for its shareholders, while the takeover was expected to have a neutral impact on Sanofi’s business earnings per share (EPS) in 2018 and 2019.


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Identifying traitors: I cannot wait until Dr. Padeniya presents his point scheme

Tuesday, 21 August 2018

Cause for excitement I am excited! A way of identifying and measuring a traitor is soon to be unveiled; by no less than the President of the GMOA! Hasn’t he also qualified in some department of neurology? All the more reason to justify my excitemen


The evils of translocating wild elephants

Tuesday, 21 August 2018

The subject of translocating wild elephants has been a much-debated topic recently, after the Department of Wildlife Conservation (DWLC), acting on the orders of the Minster for Wildlife, wanted to move the only two wild elephants habituating the Sin


Climate scientists cheating us to a $ 12 b/year economic loss in 2050

Monday, 20 August 2018

Local news media carried the disturbing pronouncement by World Bank economists to the effect that Sri Lanka will become an extremely hot territory with 30C temperature rise and $ 12 billion per year economic loss by 2050.


Singapore miracle – How SL could benefit from trade with Singapore

Monday, 20 August 2018

According to a media report released by President’s Media Division, a committee of experts has been appointed by the President to examine and report on ‘the practical impact and use of the proposed officer policy guidelines and recommendations on


Columnists More